Kåre Schultz

2019

In 2019, Kåre Schultz earned a total compensation of $11.6M as President and Chief Executive Officer at Teva Pharmaceutical Industries, a 64% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$2,869,720
Salary$2,000,000
Stock Awards$5,999,977
Other$726,867
Total$11,596,564

Schultz received $6M in stock awards, accounting for 52% of the total pay in 2019.

Schultz also received $2.9M in non-equity incentive plan, $2M in salary and $726.9K in other compensation.

Rankings

In 2019, Kåre Schultz's compensation ranked 574th out of 13,971 executives tracked by ExecPay. In other words, Schultz earned more than 95.9% of executives.

ClassificationRankingPercentile
All
574
out of 13,971
96th
Division
Manufacturing
207
out of 5,701
96th
Major group
Chemicals And Allied Products
53
out of 2,200
98th
Industry group
Drugs
44
out of 1,886
98th
Industry
Pharmaceutical Preparations
37
out of 1,398
97th
Source: SEC filing on April 22, 2020.

Schultz's colleagues

We found six more compensation records of executives who worked with Kåre Schultz at Teva Pharmaceutical Industries in 2019.

2019

Hafrun Fridriksdottir

Teva Pharmaceutical Industries

Executive Vice President, Global Research and Development

2019

Carlo de Notaristefani

Teva Pharmaceutical Industries

Former Executive Vice President, Global Operations

2019

Michael McClellan

Teva Pharmaceutical Industries

Chief Financial Officer

2019

Brendan O'Grady

Teva Pharmaceutical Industries

Executive Vice President, North America Commercial

2019

Gianfranco Nazzi

Teva Pharmaceutical Industries

Executive Vice President, International Markets Commercial

2019

Eli Kalif

Teva Pharmaceutical Industries

Chief Financial Officer

News

You may also like